Toni Choueiri: More evidence that ICI after ICI may not be effective
Toni Choueiri, Professor of Medicine at Harvard Medical School and Director of the Lank Center for Genitourinary Oncology at the Dana–Farber Cancer Institute, shared a post by Georges Gebrael, Research Fellow at Huntsman Cancer Institute and University of Utah on X, adding:
“More evidence that ICI after ICI may not be effective. This is real-world evidence to complement CONTACT-3 trial from Sumanta K. Pal et al in The Lancet.
Strong work Georges Gebrael, Neeraj Agarwal and Umang Swami.”
Quoting Georges Gebrael’s post:
“Just in ACS Journal Cancer. Patients with clear cell mRCC kidney cancer from real world Flatiron database status post ICI treatment, Similar survival with cabo and ICI vs. cabo monoRx aligning with CONTACT03 trial results.”
Source: Toni Choueiri/X and Georges Gebrael/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023